Aviado · Research
Longevity Daily
Sunday, June 14, 2026
Listen
Today's Brief
Today's anchor story comes from Nature: three blood proteins that track biological aging pace — across species — could become the foundation of a real-time aging biomarker panel, and lifestyle choices measurably shift them. A BBC Science Focus feature unpacks why serious scientists have moved from "slow aging" to "reverse it." A two-year RCT for Vitamin K2 delivers one of the more compelling cardiovascular supplement findings in recent memory. And a new study on GLP-1 drugs reveals that spontaneous physical activity drops significantly on treatment — a metabolic trade-off every user should understand.
10 stories4 peer-reviewed1 trials1 Aviado original
Cognitive Health & Neuroprotection
Repurposing Cancer Drugs to Fight Alzheimer's via mTOR: A Promising Pivot
Researchers are examining whether mTOR-targeting drugs developed for oncology — the same class that includes rapamycin — could be repurposed to treat Alzheimer's disease, where the mTOR signaling pathway is abnormally overactivated. The mechanistic logic is compelling and preclinical models have produced encouraging results, but human trial data remain limited. Worth watching as oncology's drug library increasingly becomes a longevity and neurodegeneration research toolkit.
Read more →Supplements & Compounds
Two-Year RCT: Vitamin K2 (MK-7) Cuts Coronary Artery Calcification Progression by Nearly a Third
A randomized controlled trial in patients with established coronary artery disease found that daily MK-7 supplementation was associated with nearly one-third less progression of coronary artery calcification versus placebo over 24 months — one of the most rigorous long-term K2 trials to date. Coronary artery calcification is a well-validated marker of cardiovascular risk, making this a clinically meaningful endpoint, not a surrogate. If you're already taking K2 for bone health, this trial adds a compelling cardiovascular case for staying consistent.
Read more →Neuriva, Under the Microscope: Does the Popular Brain Supplement Deliver?
Pharmacy Times examines Neuriva — one of the best-selling cognitive supplements on the market — and finds that the FDA has not evaluated the manufacturer's headline claims around memory, focus, and learning. Its two active ingredients (phosphatidylserine and coffee fruit extract) have some supporting data, but effect sizes are modest and trial quality is inconsistent. If Neuriva is on your shelf, this is a useful dose of skepticism before your next reorder.
Read more →Research & Papers
A Nature Landmark: Three Blood Proteins Reveal How Fast You're Actually Aging
A landmark study in Nature has identified three blood proteins that predict how fast an individual is biologically aging — and the biomarkers track aging consistently across both mice and humans, suggesting aging follows a deeply conserved molecular program. The panel could enable real-time biological age scoring from a simple blood draw, going beyond epigenetic clocks to capture dynamic protein-level changes. Critically, the paper also maps how lifestyle interventions and specific pharmacological agents shift these protein levels, meaning your aging trajectory is adjustable. This is the kind of cross-species, systems-level finding that could reshape what a practical 'blood test for aging' looks like within the next decade.
Read more →Social Disadvantage Accelerates Biological Aging — 140 Studies Confirm It
A sweeping meta-analysis synthesizing 1,065 effect sizes across 140 independent studies finds that social disadvantage — poverty, discrimination, chronic stress, limited education and healthcare access — measurably accelerates biological aging as captured by epigenetic clocks. The effect sizes rival those of well-known lifestyle risk factors like smoking and poor diet. For health optimizers, this is a reminder that your social and psychological environment is a powerful biological age lever, not just a backdrop to the supplements and exercise protocols.
Read more →Why Experts Now Believe Aging Can Actually Be Reversed
BBC Science Focus surveys the mounting scientific case for aging reversal — not just slowing — drawing on observations like the epigenetic clock resetting to near zero in newborns despite being built from older cells, through to recent advances in partial cellular reprogramming. The piece is notably careful, distinguishing animal model evidence from human data, while making a compelling case that the field has shifted from 'can we slow aging' to 'can we reverse it.' A well-calibrated orientation piece for anyone trying to understand why serious researchers are now this optimistic.
Read more →Aviado Research: In-Depth Longevity Science Analysis
Aviado Research publishes original analysis at the intersection of longevity science and practical health optimization, designed for readers who want evidence-graded coverage beyond the headlines. This review offers a close look at the research underpinning a key longevity topic.
Read the full Aviado analysis →Lifestyle & Nutrition
GLP-1 Drugs Linked to a Significant Drop in Spontaneous Physical Activity
A new study finds that adults with obesity who start GLP-1 receptor agonist therapy (semaglutide, tirzepatide) significantly reduce their spontaneous physical activity — the incidental movement that accounts for a substantial portion of daily energy expenditure. The paradox is real: GLP-1s suppress appetite and drive weight loss, but may simultaneously undermine one of the most metabolically valuable behaviors for long-term health. If you're on a GLP-1 drug, this finding makes a strong case for deliberately scheduling and protecting your daily movement.
Read more →Industry & Policy
FDA, ARPA-H, and XPRIZE Map a Regulatory Path for the First True Longevity Drugs
On May 27, the Reagan-Udall Foundation for the FDA convened a full-day public meeting alongside ARPA-H and the XPRIZE Foundation to address how aging-targeting drugs could earn clinical approval — the most substantive public regulatory conversation the longevity field has seen. The core problem remains: current FDA frameworks require disease-specific endpoints, and aging itself is not a recognized indication. This meeting signals real momentum toward a framework that could make geroscience treatments both approvable and investable.
Read more →NHS Clinicians Are Spending Precious Appointment Time Countering Supplement Myths
A YouGov poll for the World Cancer Research Fund found that 53% of NHS nurses and midwives report patients arriving with supplement misinformation — typically sourced from social media — that consumes significant clinical time and raises real patient safety concerns. Doctors describe the phenomenon as a growing burden on consultations. For supplement-savvy readers, this is a useful reminder that the information ecosystem around nutrition and longevity carries heavy noise, making source quality and evidence grading more important than ever.
Read more →